Thursday 17 May 2018

Reuters Health Report: Walgreen, Kroger, Albertsons, HEB sue Allergan over dry-eye drug

Walgreen, Kroger, Albertsons, HEB sue Allergan over dry-eye drug

NEW YORK (Reuters) - Allergan Inc was sued on Wednesday by four large U.S. retailers that accused the drugmaker of antitrust violations for trying to stop rivals from selling generic versions of Restasis, its medication to treat dry-eye disease.

Congo health minister says Ebola outbreak in "new phase" after urban case

KINSHASA (Reuters) - Congo Health Minister Oly Ilunga Kalenga late on Wednesday said in a statement that the country's Ebola outbreak had entered "a new phase" after a case of the virus was detected in the northwest city of Mbandaka, with a population of about 1 million people.

FDA approves first non-opioid drug to treat opioid withdrawal symptoms

(Reuters) - The U.S. Food and Drug Administration on Wednesday approved https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm607884.htm the first non-opioid drug that will help reduce symptoms of opioid withdrawal in adults.

Roche immunotherapy combination increases lung cancer survival - study

(Reuters) - Roche's immunotherapy Tecentriq, given with its older drug Avastin and chemotherapy, improved survival of advanced lung cancer patients by about 30 percent over the combination without Tecentriq, according to interim results of a late stage trial released on Wednesday.

FDA says harvest season over for E. coli-linked romaine lettuce

(Reuters) - The U.S. Food and Drug Administration said on Wednesday the harvest season for romaine lettuce, linked to the multi-state E. coli outbreak, was over and it was unlikely that it was still available in stores due to its 21-day shelf life.

Roche breast cancer drug treatment time can be halved - study

(Reuters) - Treating early stage breast cancer patients for just six months with Roche's Herceptin works as well as the current 12-month regimen, researchers who conducted a large clinical trial said on Wednesday.

Merck's Keytruda boosts response in hard-to-treat lung cancer

(Reuters) - The combination of Merck & Co's immunotherapy Keytruda and chemotherapy boosted response rates in patients with advanced hard-to-treat squamous cell lung cancer, the company said on Wednesday.

Merck KGaA's lung cancer drugs show promise in early-stage trials

FRANKFURT (Reuters) - Germany's Merck KGaA said two of its experimental oncology drugs showed early signs of promise in certain lung cancer patients, potentially helping efforts to find drug-industry partners to share further development costs.

Loxo Oncology's targeted RET drug shows promise in early trial

CHICAGO (Reuters) - An experimental Loxo Oncology Inc drug that targets cancers with mistakes in the RET gene led to tumor shrinkage in nearly 70 percent of patients regardless of where their cancer originated, according to preliminary data from a small study released on Wednesday.

Congo receives first doses of Ebola vaccine amid outbreak

GENEVA/KINSHASA (Reuters) - The first batch of 4,000 experimental Ebola vaccines to combat an outbreak suspected of killing 23 people arrived in Congo's capital Kinshasa on Wednesday.

Related Videos

Hybrid-electric aircraft race heats up

Hemp-made electric scooter riding high in Amsterdam

You might like...

Check out our Reuters News Now daily briefing for hand-picked stories from Reuters editors. It's all the news you need to start your day.

Subscribe here